Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Fulgent Genetics (NASDAQ: FLGT) announced it will release its Q2 2021 financial results on August 5, 2021, after market close. Following this, a conference call will be hosted by CEO Ming Hsieh and other executives at 4:30 PM ET to discuss the results and answer questions. The company’s innovative technology platform offers extensive testing solutions, including full-gene sequencing and tailored options, ensuring high accuracy and competitive turnaround times, aimed to address diverse customer needs.
- Innovative technology platform offering extensive genetic testing solutions.
- Ability to tailor tests to meet specific customer requirements.
- None.
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (800) 437-2398 using the confirmation code 5019459. An audio replay will be available in the Investors section of the company’s website.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005233/en/
FAQ
What is the date of Fulgent Genetics Q2 2021 financial results release?
What time is the Fulgent Genetics conference call for Q2 2021 results?
How can I access the live webcast for Fulgent Genetics Q2 2021 results?
Who will host the conference call for Fulgent Genetics Q2 2021 financial results?
